Loading...

SLXN SILEXION THERAPEUTICS CORP Expansion Plans 8-K Filing

SLXN

SLXN

SILEXION THERAPEUTICS CORP

(SLXN)

2025 8-K

Director Removed

Clinical Trial Approval

Shareholder Meeting Results

Investor Presentation Annou...

CEO Letter Highlights

Clinical Trial Application

Positive Feedback Received

Toxicology Study Success

Financial Results Update

Positive Data Announced

New Offering Agreement

Compliance Confirmed

Share Issuance Update

Public Offering Details

Positive Preclinical Data

Clinical Trial Support

Corporate Presentation Update

Share Split Update

Share Capital Increase

Rights Offerings

Product Expansion

Reverse Share Split

Reverse Share Split

Reverse Stock Split

Clinical Trials

Listing Transfer

Nasdaq Delisting Notice

Voluntary Delisting

Product Expansion

Voluntary Delisting

Product Expansion

Financial Statements

Development Plan

Financial Results

Positive Data Release

Warrant Agreement

Tumor Growth Reduction

Public Offering

Share Purchase Amendment

Corporate Presentation

Financial Update

Collaboration Announcement

Board Appointment

Corporate Update

Compliance Issues

Share Split Approval

Financial Results

Nasdaq Deficiency Notice

External Links:

On September 30, 2025, Silexion Therapeutics Corp announced new human cell line data showing that its drug SIL204 achieved up to 99.7% inhibition against pan-KRAS activity and the first evidence of effectiveness in gastric cancer.

AI Assistant

SILEXION THERAPEUTICS CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.